Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a primary diagnosis of ADHD~* Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements~Exclusion Criteria:~* Subject has current uncontrolled comorbid psychiatric diagnosis (except ODD) with significant symptoms~* History of seizure during the last 2 years~* Subject has any specific cardiac condition or family history of significant cardiac condition~* Subject is pregnant or lactating

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- SPD503 (Guanfacine HCl) (2 mg) (Type: EXPERIMENTAL): None
- SPD503 (3 mg) (Type: EXPERIMENTAL): None
- SPD503 (4 mg) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).